MPTP (hydrochloride) [23007-85-4]
Cat# HY-15608-100mg
Size : 100mg
Brand : MedChemExpress
Chlorhydrate de MPTP est une neurotoxine de dopamine pénétrante dans le cerveau, induisant la maladie de Parkinson. Chlorhydrate de MPTP, précurseur du MPP+, induit l'apoptose.
MPTP-Hydrochlorid ist ein hirneindringendes dopamine-Neurotoxin, das die Parkinson-Krankheit auslöst. MPTP-Hydrochlorid, ein Vorläufer von MPP+, induziert apoptosis.
MPTP hydrochloride is a brain penetrant dopamine neurotoxin. MPTP hydrochloride can be used to induces Parkinson’s Disease model. MPTP hydrochloride, a precusor of MPP+, induces apoptosis. MPTP hydrochloride has been verified by MCE with professional biological experiments.
For research use only. We do not sell to patients.
MPTP hydrochloride Chemical Structure
CAS No. : 23007-85-4
Size | Price | Stock | Quantity |
---|---|---|---|
Free Sample (0.1 - 0.5 mg) | Apply Now | ||
Solid + Solvent | |||
10 mM * 1 mL
in DMSO
ready for reconstitution
|
USD 66 | In-stock | |
Solution | |||
10 mM * 1 mL in DMSO | USD 66 | In-stock | |
Solid | |||
5 mg | USD 38 | In-stock | |
10 mg | USD 60 | In-stock | |
50 mg | USD 180 | In-stock | |
100 mg | USD 264 | In-stock | |
200 mg | USD 450 | In-stock | |
500 mg | USD 600 | In-stock | |
1 g | Get quote | ||
5 g | Get quote |
* Please select Quantity before adding items.
This product is a controlled substance and not for sale in your territory.
Based on 35 publication(s) in Google Scholar
- •Signal Transduct Target Ther. 2021 Feb 24;6(1):77. [Abstract]
- •Cell Death Dis. 2021 Feb 15;12(2):181. [Abstract]
- •Cell Death Dis. 2019 Dec 16;10(12):952. [Abstract]
- •Antioxidants (Basel). 2023 Nov 13, 12(11), 1999.
- •J Med Chem. 2023 Aug 31. [Abstract]
- •Cell Death Discov. 2022 May 20;8(1):267. [Abstract]
- •J Ethnopharmacol. 2024 May 10:325:117857. [Abstract]
- •CNS Neurosci Ther. 2023 Aug 11. [Abstract]
- •Front Aging Neurosci. 2023 Jan 25.
- •Pharmaceutics. 2022, 14(8), 1731.
- •Bioelectrochemistry. 2020 Aug;134:107532. [Abstract]
- •Int J Pharm. 2020 Mar 15;577:119053. [Abstract]
- •Neurotox Res. 2023 Jan 27. [Abstract]
- •Neurosci Lett. 2021 Jan 10;741:135493. [Abstract]
- •Heliyon. 2020 Jul 11;6(7):e04425. [Abstract]
- •Toxicol Sci. 2020 Oct 1;177(2):506-520. [Abstract]
- •Brain Res. 2020 Nov 1;1746:147023. [Abstract]
- •Biochem Biophys Res Commun. 2020 Jun 11;526(4):1013-1020. [Abstract]
- •Neurotox Res. 2020 Jun;38(1):27-37. [Abstract]
- •Brain Res. 2020 Jan 1;1726:146493. [Abstract]
- •Brain Res. 2019 Oct 15;1721:146334. [Abstract]
- •Brain Res. 2019 Jul 15;1715:203-212. [Abstract]
- •Pharmacol Biochem Behav. 2019 Feb;177:1-11. [Abstract]
- •Brain Res. 2016 Jul 1;1642:546-552. [Abstract]
- •J Integr Neurosci. 2024 Feb 4;23(2):29. [Abstract]
- •Charles University. 2024 Jan 29.
- •bioRxiv. 2023 Jun 26.
- •IBRO Neurosci Rep. 27 November 2021.
- •Research Square Preprint. 2021 Jun.
- •University of Szeged. Department of Neurology Faculty of Medicine. 2020 Dec.
- •AfricArXiv Preprints. 2019 Aug.
-
MPTP hydrochloride purchased from MedChemExpress. Usage Cited in: Brain Res. 2019 Jul 15;1715:203-212. [Abstract]
- Immunofluorescence for TH. The intranigral Apelin-13 injection significantly inhibits MPTP-induced the neurodegeneration of dopaminergic neurons in the SNpc.
-
MPTP hydrochloride purchased from MedChemExpress. Usage Cited in: Pharmacol Biochem Behav. 2019 Feb;177:1-11. [Abstract]
- Effect of treatment with Rapamycin, trehalose, or their combination on tyrosine hydroxylase (TH) expression in the striatum in MPTP-induced mouse model of Parkinson’s disease.
-
MPTP hydrochloride purchased from MedChemExpress. Usage Cited in: Pharmacol Biochem Behav. 2019 Feb;177:1-11. [Abstract]
- Effect of treatment with Rapamycin, trehalose, or their combination on autophagy activity measured by quantified immunoreactivity of LC3-II in the s. nigra. MPTP is administered at the dose of 20 mg/kg (i.p., daily) for 4 days to induce PD-like pathology.
-
MPTP hydrochloride purchased from MedChemExpress. Usage Cited in: Brain Res. 2016 Jul 1;1642:546-552. [Abstract]
- RNA 5hmC decreases in a MPTP-induced Parkinson's disease mouse model. MPTP (i.p. 60 mg/kg) is injected to induce Parkinson's disease model in mice. At 24 h after last MPTP injection, open field test is performed. After behavioral tests, the hippocampus (Hipo), the substantia nigra (SN), the striatum (Str), and the cortex (Ctx) are collected and total RNA is extracted. Total 100 ng RNA is used for dot blot analysis to detect 5hmC abundance in RNA samples from different brain regions. Methylene bl
•Related Screening Libraries:
•Related Small Molecules:
•Related Proteins:
View All Dopamine Receptor Isoform Specific Products:
Biological Activity
Protocol
Purity & Documentation
References
Customer Review
Description | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Pretreatment with 50 mM 4-phenylpyridine, reduces IC50 (concentration for 50% inhibition of twitch amplitude) values of MPTP from 53 to 18 mM and d-tubocurarine from 0.7 to 0.3 mM, respectively, in mouse phrenic nerve-diaphragm[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
Although MPTP can be administered by a variety of different routes, including oral gavage and stereotaxic injection into the brain, the most common, and reproducible, results are obtained by systemic subcutaneous (s.c.) or intraperitoneal (i.p.) injection. The commonly used protocols in the references are acute model (14-20 mg/kg, i.p., given every 2 hours within a day, a total of 4 times) and subacute model (30 mg/kg, i.p., once daily for 5 days). MPTP is quickly metabolized to MPP+ after injection, and MPP+ has a half-life of about 6 days in sheep (serum). MPTP hydrochloride can be used in animal modeling to build Parkinson's syndrome models. MPTP reproduces the naturally occurring neurodegeneration and are useful for studying dopaminergic neuron neurodegeneration, mitochondrial dysfunction and neuroinflammation[8]. Background
MPTP is free to cross the blood-brain barrier and enter the brain, where it is metabolized by monoamine oxidase B (MAO-B) in astrocytes into MPP+, its active & toxic form. MPP+ is taken up by dopamine neurons via a dopamine transporter (DAT), blocking Complex I in the electron transport chain of mitochondria, triggering oxidative stress and mitochondrial breakdown, and finally leading to neuron apoptosis. In Parkinson's disease, it is the loss of neurons in the substantia nigra, the dopamine-producing part of the substantia nigrostriatum system, that causes the disease. Due to the toxic effects of MPTP, it will cause the death of dopamine neurons in the substantia nigra, causing symptoms similar to Parkinson's disease.
Specific Mmodeling Methods
Mice: C57BL/6 • male • 8-12 week-old (period: 2 weeks), older mice may be more sensitive Administration: Acute model: 14-20 mg/kg • ip • 4 times a day, two hours apart Sub-acute model: 30 mg/kg • ip • once daily for 5 days
Note
MPTP Hcl is dissolved in normal saline and configured when used.
After administration, we can observe whether the mice have symptoms such as reduced activity, staggering walking, twitching, fried hair, increased urination, etc. This behavior may last for 24-48 hours, after which the mice behave basically normally. MPTP is usually sold as MPTP hydrochloride. The molecular weight of MPTP hydrochloride is 209.7. Therefore, it is recommended to take into account the presence of hydrochloride (HCl) when preparing injectable solutions. HCl has a molecular weight of 35.4 and accounts for 17% of MPTP. Thus, if a 20 mg/kg dose of MPTP is to be prepared, the MPTP hydrochloride dose administered is 20 mg kg* 1.17% = 23.4 mg/kg. If multiple injections are given within 1 day, it is best to alternate the injections on both sides. If injected every day, it should be done at the same time. Before each injection, the mice need to be weighed and the dosage volume should be adjusted. Modeling mice may not show behavioral defects of Parkinson's disease. Mice may show individual differences, and the success rate of modeling is generally difficult to reach 100%. Therefore nigrostriatal damage associated with gliosis should be mainly monitored in MPTP mouse studies. High drug dosage/mice weighing less than 22 g/mixing of drugs from different batches/mice not adapting in advance/animal room being too cold may result in a number of deaths, and it is recommended that the number of animals in each group be increased. Modeling Indicators
Nigrostriatal injury: Tyrosine hydroxylase in the substantia nigra and striatum is reduced after successful modeling (IHC, IF, WB, etc.);
Other markers: reduction of brain neurotransmitters (DA, DOPAC, 5-HT, HVA, etc.) (detected by HPLC); Nigrostriatal microglia (IBA1+ cells) and astrocytes (GFAP+ cells) are activated, and the number of α-syn aggregates in the substantia nigra . Opposite Product(s): L-Carnosine (HY-W013494) MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Molecular Weight |
209.72 |
||||||||||||
Formula |
C12H16ClN |
||||||||||||
CAS No. | |||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
SMILES |
CN1CC=C(C2=CC=CC=C2)CC1.08Cl |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
4°C, sealed storage, away from moisture *In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture) |
||||||||||||
Solvent & Solubility |
In Vitro:
H2O : ≥ 100 mg/mL (476.83 mM) DMSO : 12 mg/mL (57.22 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration:
mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
|
||||||||||||
Purity & Documentation |
Purity: 99.54% |
||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO / H2O | 1 mM | 4.7683 mL | 23.8413 mL | 47.6826 mL | 119.2066 mL |
5 mM | 0.9537 mL | 4.7683 mL | 9.5365 mL | 23.8413 mL | |
10 mM | 0.4768 mL | 2.3841 mL | 4.7683 mL | 11.9207 mL | |
15 mM | 0.3179 mL | 1.5894 mL | 3.1788 mL | 7.9471 mL | |
20 mM | 0.2384 mL | 1.1921 mL | 2.3841 mL | 5.9603 mL | |
25 mM | 0.1907 mL | 0.9537 mL | 1.9073 mL | 4.7683 mL | |
30 mM | 0.1589 mL | 0.7947 mL | 1.5894 mL | 3.9736 mL | |
40 mM | 0.1192 mL | 0.5960 mL | 1.1921 mL | 2.9802 mL | |
50 mM | 0.0954 mL | 0.4768 mL | 0.9537 mL | 2.3841 mL | |
H2O | 60 mM | 0.0795 mL | 0.3974 mL | 0.7947 mL | 1.9868 mL |
80 mM | 0.0596 mL | 0.2980 mL | 0.5960 mL | 1.4901 mL | |
100 mM | 0.0477 mL | 0.2384 mL | 0.4768 mL | 1.1921 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
MPTP hydrochloride Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Bulk Inquiry
Inquiry Information
- Product Name:
- MPTP hydrochloride
- Cat. No.:
- HY-15608
- Quantity:
- MCE Japan Authorized Agent: